The FDA has converted its 2024 accelerated approval of tarlatamab-dlle (Imdelltra) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression during or ...

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

Biomarker testing for patients with ovarian cancer should be completed both in the upfront setting and through disease ...

Nivolumab displayed significant RFS benefit compared with ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma. Adjuvant treatment with nivolumab (Opdivo) led to durable efficacy vs ...

Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic ...

Panelists discuss how specific talquetamab-related side effects like skin peeling, nail changes, and rashes can be effectively managed through targeted interventions including topical treatments, ...

Panelists discuss how healthcare providers can develop comprehensive management protocols for talquetamab-related toxicities ...

Panelists discuss how comprehensive patient education materials and manufacturer resources help patients prepare for and ...

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, ...

Panelists discuss how healthcare providers must actively educate local oncologists, emergency departments, and community ...

JADPRO Live 2025 provides a platform for leaders in oncology advanced practice to share research and best practices with ...